aTyr Pharma (ATYR) Price & Analysis

Compare

2,500 Followers

ATYR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.67 - $7.29

Previous CloseN/A

Volume346.43K

Average Volume (3M)5.43M

Market Cap

$464.60M

Enterprise Value$197.64M

Total Cash (Recent Filing)$76.35M

Total Debt (Recent Filing)$12.99M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Nov 06, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding89,004,430

10 Day Avg. Volume7,962,427

30 Day Avg. Volume5,431,755

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.43

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-3.00

Forecast

1Y Price Target

$22.33

Price Target Upside327.78% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical PotentialEfzofitimod has the potential to dramatically improve the treatment of pulmonary sarcoidosis, addressing a significant clinical demand where current treatments are limited and risky.

Investment OpportunityInsights reaffirm the view that the Ph 3 EFZO-FIT trial of efzo in pulmonary sarcoidosis offers an attractive high-risk high-reward investment opportunity.

Bears Say

Data Interpretation ChallengesKey recurring questions have included interpreting the infamous table on clinicaltrials.gov that implies placebo beat drug on maintaining taper.

Unanswered QuestionsSeveral unanswered or unanswerable questions on the underlying science and precedent clinical data handicap investor ability to diligence the catalyst.

aTyr Pharma News

aTyr Pharma files $300M mixed securities shelf

16:24 EDT aTyr Pharma (ATYR) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

5h ago

ATYR

aTyr Pharma reports Q2 EPS (22c), consensus (18c)

“With the recent completion of the last patient visit in our Phase 3 EFZO-FIT(TM) study of efzofitimod in...

5h ago

ATYR

aTyr Pharma Inc put volume heavy and directionally bearish

Bearish flow noted in aTyr Pharma (ATYR) Inc with 4,292 puts trading, or 2x expected. Most active are...

10h ago

ATYR

aTyr Pharma Inc put volume heavy and directionally bearish

Bearish flow noted in aTyr Pharma (ATYR) Inc with 10,964 puts trading, or 9x expected. Most active are...

9d ago

ATYR

aTyr Pharma management to meet with Cantor Fitzgerald

Meetings to be held in Denver July 30-31 hosted by Cantor Fitzgerald. Published first on TheFly – the...

10d ago

ATYR

aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study

aTyr Pharma (ATYR) announced that the last patient has completed their last visit in the Company’s Phase 3...

17d ago

ATYR

Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial

aTyr Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Faisal Khurshid from...

7d ago

ATYR

High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on aTyr Pharma and keeping the price target...

16d ago

ATYR

Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on aTyr Pharma. The associated price target...

16d ago

ATYR

Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential

aTyr Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

29d ago

ATYR

Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on aTyr Pharma (ATYR...

1M ago

ATYR

aTyr Pharma to be added to Russell 2000, Russell 3000 Indices

aTyr Pharma (ATYR) announced that the Company is expected to be added to the Russell 2000 Index and...

1M ago

ATYR

aTyr Pharma price target raised to $25 from $17 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on aTyr Pharma (ATYR) to $25 from $17...

2M ago

ATYR

Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) and...

2M ago

ATYR

ATYR FAQ

What was Atyr Pharma Inc.’s price range in the past 12 months?

Atyr Pharma Inc. lowest stock price was $1.67 and its highest was $7.29 in the past 12 months.

What is Atyr Pharma Inc.’s market cap?

Atyr Pharma Inc.’s market cap is $464.60M.

When is Atyr Pharma Inc.’s upcoming earnings report date?

Atyr Pharma Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Atyr Pharma Inc.’s earnings last quarter?

Atyr Pharma Inc. released its earnings results on Aug 07, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.035.

Is Atyr Pharma Inc. overvalued?

According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atyr Pharma Inc. pay dividends?

Atyr Pharma Inc. does not currently pay dividends.

What is Atyr Pharma Inc.’s EPS estimate?

Atyr Pharma Inc.’s EPS estimate is -0.16.

How many shares outstanding does Atyr Pharma Inc. have?

Atyr Pharma Inc. has 89,004,430 shares outstanding.

What happened to Atyr Pharma Inc.’s price movement after its last earnings report?

Atyr Pharma Inc. reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went up 5.696%.

Which hedge fund is a major shareholder of Atyr Pharma Inc.?

Currently, no hedge funds are holding shares in ATYR

aTyr Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-79.51%

Trailing 12-Months

Asset Growth

-14.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atyr Pharma Inc.

aTyr Pharma (ATYR) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. The company's primary focus lies in the research and development of therapeutics derived from unique protein interactions within the human body, particularly targeting immune, fibrotic, and other serious diseases. aTyr Pharma operates within the biotechnology and pharmaceuticals sectors, aiming to address significant unmet medical needs through its cutting-edge scientific approaches.

aTyr Pharma (ATYR) Earnings & Revenues

Historic Earnings Reports

ATYR Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.View all ATYR earnings summaries

ATYR Stock 12 Month Forecast

Average Price Target

$22.33

▲(327.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","27":"$27","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,9,18,27,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,7.030769230769231,9.361538461538462,11.692307692307693,14.023076923076925,16.353846153846156,18.684615384615384,21.015384615384615,23.346153846153847,25.676923076923078,28.00769230769231,30.33846153846154,32.66923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,6.056153846153846,7.412307692307692,8.768461538461537,10.124615384615385,11.48076923076923,12.836923076923075,14.193076923076923,15.549230769230768,16.905384615384616,18.26153846153846,19.617692307692305,20.97384615384615,{"y":22.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.569230769230769,6.438461538461539,7.307692307692308,8.176923076923078,9.046153846153846,9.915384615384616,10.784615384615385,11.653846153846153,12.523076923076925,13.392307692307693,14.26153846153846,15.130769230769232,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >